Mallinckrodt says its acute pain drug met primary endpoints in Phase III testing

|About: Mallinckrodt PLC (MNK)|By:, SA News Editor

Mallinckrodt (MNK +2.3%) trades up after saying its investigational drug MNK-795 showed statistically significant improvement in pain scores compared to a placebo during Phase III testing for treatment of acute pain following bunion removals.

The drug's New Drug Application was accepted by the FDA in July and granted priority review.